✓ Translated by DotMD AI Clinical Council Source: Skin pharmacology and physiology • Randomized Controlled Trial
Verify Primary Source: NIH PubMed PMID #29055953 ↗

Randomized Controlled Trial: An Open-Label Randomized Multicenter Study Assessing the Noninferiority of a Caffeine-Based Topical Liquid 0.2% versus Minoxidil 5% Solution in Male Androgenetic Alopecia (N = 210)

Original Paper Title: “An Open-Label Randomized Multicenter Study Assessing the Noninferiority of a Caffeine-Based Topical Liquid 0.2% versus Minoxidil 5% Solution in Male Androgenetic Alopecia”

Elena Rostova (AI Quant) Rigor Score
82 / 100
Sample Size (Participants)
N = 210
Evidence Classification
Randomized Controlled Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • A caffeine-based topical liquid should be considered as not inferior to minoxidil 5% solution in men with androgenetic alopecia.
  • Study Design & Sample: Randomized Controlled Trial published in Skin pharmacology and physiology (N = 210 human participants).
  • Biostatistical Rigor Score: 82/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Skin pharmacology and physiology (2017), this randomized controlled trial evaluating 210 human participants investigated: Androgenetic alopecia is a condition with a high prevalence worldwide and affects both males and females. Key clinical takeaway: A caffeine-based topical liquid should be considered as not inferior to minoxidil 5% solution in men with androgenetic alopecia.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Skin pharmacology and physiology, 2017-01-15; N = 210; Rigor 82/100): A caffeine-based topical liquid should be considered as not inferior to minoxidil 5% solution in men with androgenetic alopecia.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Randomized Controlled Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: oral-ivy-liquid-toxicodendron-pubescens-leaf → Rx: minoxidil → Rx: stay-minoxidil-hair-regrowth-treatment-minoxidil-5 → Rx: caffeine-citrate → Condition: caffeine → Condition: nonscarring-hair-loss → Condition: beaus-lines →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 29055953: Randomized Controlled Trial: An Open-Label Randomized Multicenter Study Assessing the Noninferiority of a Caffeine-Based Topical Liquid 0.2% versus Minoxidil 5% Solution in Male Androgenetic Alopecia (N = 210)

3 of 3 Free Questions Remaining